Literature DB >> 18347349

Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals.

Ari Robicsek1, Jennifer L Beaumont, Suzanne M Paule, Donna M Hacek, Richard B Thomson, Karen L Kaul, Peggy King, Lance R Peterson.   

Abstract

BACKGROUND: The effect of large-scale expanded surveillance for methicillin-resistant Staphylococcus aureus (MRSA) on health care-associated MRSA disease is not known.
OBJECTIVE: To examine the effect of 2 expanded surveillance interventions on MRSA disease.
DESIGN: Observational study comparing rates of MRSA clinical disease during and after hospital admission in 3 consecutive periods: baseline (12 months), MRSA surveillance for all admissions to the intensive care unit (ICU) (12 months), and universal MRSA surveillance for all hospital admissions (21 months).
SETTING: A 3-hospital, 850-bed organization with approximately 40,000 annual admissions. INTERVENTION: Polymerase chain reaction-based nasal surveillance for MRSA followed by topical decolonization therapy and contact isolation of patients who tested positive for MRSA. MEASUREMENTS: Poisson and segmented regression models were used to compare prevalence density of hospital-associated clinical MRSA disease (bloodstream, respiratory, urinary tract, and surgical site) in each period. Rates of bloodstream disease with methicillin-susceptible S. aureus were used as a control.
RESULTS: The prevalence density of aggregate hospital-associated MRSA disease (all body sites) per 10,000 patient-days at baseline, during ICU surveillance, and during universal surveillance was 8.9 (95% CI, 7.6 to 10.4), 7.4 (CI, 6.1 to 9.0; P = 0.15 compared with baseline), and 3.9 (CI, 3.2 to 4.7; P < 0.001 compared with baseline and ICU surveillance), respectively. During universal surveillance, the prevalence density of MRSA infection at each body site had a statistically significant decrease compared with baseline. The methicillin-susceptible S. aureus bacteremia rate did not statistically significantly change during the 3 periods. In a segmented regression model, the aggregate hospital-associated MRSA disease prevalence density changed by -36.2% (CI, -65.4% to 9.8%; P = 0.17) from baseline to ICU surveillance and by -69.6% (CI, -89.2% to -19.6%]; P = 0.03) from baseline to universal surveillance. During universal surveillance, the MRSA disease rate decreased during hospitalization and in the 30 days after discharge; no further reduction occurred thereafter. Surveillance with clinical cultures would have identified 17.8% of actual MRSA patient-days, and ICU-based surveillance with polymerase chain reaction would have identified 33.3%. LIMITATION: The findings rely on observational data.
CONCLUSION: The introduction of universal admission surveillance for MRSA was associated with a large reduction in MRSA disease during admission and 30 days after discharge.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347349     DOI: 10.7326/0003-4819-148-6-200803180-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  111 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

2.  Methicillin-resistant Staphylococcus aureus colonization at different body sites: a prospective, quantitative analysis.

Authors:  Leonard A Mermel; Jennifer M Cartony; Pauline Covington; Gail Maxey; Dan Morse
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

3.  Role of decolonization in a comprehensive strategy to reduce methicillin-resistant Staphylococcus aureus infections in the neonatal intensive care unit: an observational cohort study.

Authors:  Aaron M Milstone; Alicia Budd; John W Shepard; Tracy Ross; Susan Aucott; Karen C Carroll; Trish M Perl
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

4.  Decontamination strategies for MRSA-colonized patients.

Authors:  Mark S Pasternack
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

5.  A common variant of staphylococcal cassette chromosome mec type IVa in isolates from Copenhagen, Denmark, is not detected by the BD GeneOhm methicillin-resistant Staphylococcus aureus assay.

Authors:  Mette Damkjaer Bartels; Kit Boye; Susanne Mie Rohde; Anders Rhod Larsen; Herbert Torfs; Peggy Bouchy; Robert Skov; Henrik Westh
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

6.  Automation of the BD GeneOhm methicillin-resistant Staphylococcus aureus assay for high-throughput screening of nasal swab specimens.

Authors:  Xue-Ping Wang; Christine C Ginocchio
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

7.  Multicenter evaluation of the Cepheid Xpert methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares.

Authors:  D M Wolk; E Picton; D Johnson; T Davis; P Pancholi; C C Ginocchio; S Finegold; D F Welch; M de Boer; D Fuller; M C Solomon; B Rogers; M S Mehta; L R Peterson
Journal:  J Clin Microbiol       Date:  2009-01-07       Impact factor: 5.948

8.  A perspective on how the United States fell behind Northern Europe in the battle against methicillin-resistant Staphylococcus aureus.

Authors:  Kevin T Kavanagh; Daniel M Saman; Yanling Yu
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

9.  Enteral vancomycin and probiotic use for methicillin-resistant Staphylococcus aureus antibiotic-associated diarrhoea.

Authors:  Elizabeth Nicole Sizemore; Kenya Maria Rivas; Jose Valdes; Joshua Caballero
Journal:  BMJ Case Rep       Date:  2012-07-27

10.  Epidemiology of methicillin-resistant Staphylococcus aureus carriage and MRSA surgical site infections in patients undergoing colorectal surgery: a cohort study in two centers.

Authors:  Benedikt Huttner; Ari A Robicsek; Pascal Gervaz; Eli N Perencevich; Eduardo Schiffer; Jacques Schrenzel; Stephan Harbarth
Journal:  Surg Infect (Larchmt)       Date:  2012-12-16       Impact factor: 2.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.